Nano‐RECall provides an integrated pipeline for HIV‐1 drug resistance testing from Oxford Nanopore sequence data. Issue 3 (13th January 2023)

• Record Type: Journal Article
• Authors: Delaney, Kayla Eileen; Ngobeni, Trevor; Woods, Conan K.; Gordijn, Carli; Claassen, Mathilda; Parikh, Urvi; Harrigan, P. Richard; van Zyl, Gert Uves
• Is Part Of: Tropical medicine & international health. Volume 28:Issue 3(2023)
• Page Start: 186
• Page End: 193
• Publication Date: 2023-01-13
• Subjects: bioinformatics pipeline -- codon‐aware alignment -- HIV drug resistance sequencing -- homopolymer error -- Oxford Nanopore Technology -- sanger sequencing; Tropical medicine -- Periodicals; Public health -- Periodicals; 616.988
• DOI: 10.1111/tmi.13851
• Languages: English
• ISSNs: 1360-2276

Abstract

Abstract: Objectives: Low‐capital‐layout sequencing options from Oxford Nanopore Technologies (ONT) could assist in expanding HIV drug resistance testing to resource‐limited settings. HIV drug resistance mutations often occur as mixtures, but current ONT pipelines provide a consensus sequence only. Moreover, there is no integrated pipeline that provides a drug resistance report from an ONT sequence file without intervention from skilled bioinformaticists. We therefore investigated Nano‐RECall, which provides seamless drug resistance interpretation while requiring low‐read coverage ONT sequence data from affordable Flongle or MinION flow cells and which provides mutation mixtures similar to Sanger Sequencing. Methods: We compared Sanger sequencing to ONT sequencing of the same HIV‐1 subtype C polymerase chain reaction (PCR) amplicons, respectively using RECall and the novel Nano‐RECall bioinformatics pipelines. Amplicons were from separate assays: (a) Applied Biosystems HIV‐1 Genotyping Kit (ThermoFisher) spanning protease (PR) to reverse transcriptase (RT) (PR‐RT) ( n = 46) and (b) homebrew integrase (IN) ( n = 21). The agreement between Sanger sequences and ONT sequences was assessed at nucleotide level, and at codon level for Stanford HIV drug resistance database mutations at an optimal ONT read depth of 400 reads only. Results: The average sequence similarity between ONT and Sanger sequences was 99.3% (95% CI: 99.1%–99.4%) for PR‐RT and 99.6% (95% CI: 99.4%–99.7%) for INT. Drug resistance mutations did not differ for 21 IN specimens; 8 mutations were detected by both ONT‐ and Sanger sequencing. For the 46 PR and RT specimens, 245 mutations were detected by either ONT or Sanger, of these 238 (97.1%) were detected by both. Conclusions: The Nano‐RECall pipeline, freely available as a downloadable application on a Windows computer, provides Sanger‐equivalent HIV drug resistance interpretation. This novel pipeline combined with a simple workflow and multiplexing samples on ONT flow‐cells would contribute to making HIV drug resistance sequencing feasible for resource‐limited settings.